Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Patient demographic and treatment characteristics; percentiles are listed parenthetically.

From: Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme

Characteristic

  

Series

Primary disease

Recurrent disease

   

(n = 42)

(n = 33)

(n = 9)

Age (yrs)

     
 

Median

 

60

63

46

 

Range

 

20–86

40–86

20–59

Sex

     
 

Male

 

27 (64)

20 (60)

7 (78)

 

Female

 

15 (36)

13 (40)

2 (22)

Surgery

     
 

Biopsy alone/unresectable

 

8 (19)

6 (19)

2 (22)

 

Debulking/resection

 

34 (81)

27 (81)

7 (78)

  

Complete resection

13(31)

10 (30)

3 (33)

  

Partial resection

21(50)

17 (51)

4 (44)

Chemotherapy

None

 

19 (45)

17 (51)

2 (22)

 

Any agent

 

23 (55)

16 (49)

7 (78)

  

Carmustine (iv)

5 (12)

2 (6)

3 (33)

  

Carmustine (wafer)

2 (5)

1 (3)

1 (11)

  

Lomustine

1 (2)

1 (3)

-

  

Irinotecan

3(7)

2 (6)

1 (11)

  

Penicillamine

3 (7)

3 (9)

-

  

Temozolomide

9(21)

7 (21)

2 (22)

IMRT technique

     
 

IMRT Only

 

30 (72)

22 (66)

8 (89)

 

3DCRT + IMRT boost

 

12 (28)

11 (33)

1 (11)